Gustavo Pesquin’s Post

We’re excited to share that AB-1005, which is being developed for moderate Parkinson’s disease, received US FDA Fast Track and UK MHRA Innovation Passport designations. There's a huge unmet need for #Parkinson's treatment, and these designations take us another step closer to accelerating access for patients. We at #AskBio, alongside Bayer | Pharmaceuticals, are dedicated to providing patients with innovative therapies and, most importantly, improving patient outcomes. #genetherapy   For Medical Media – Read our press release here: https://lnkd.in/g7Mr854f  

With a new pharmaceutical legislation in the making, Europe finds itself at a crossroads. This is a critical time for the innovation-driven pharmaceutical industry in Europe. Europe’s R&D investments have significantly fallen behind other regions in the world, most notably the United States and China. In today’s era of breakthrough innovation, the question is not if medical progress will happen, but rather where it will happen, given that the global competition for cutting-edge science and new investments is fierce. Since 2014, only 56% of new drug innovations have been approved in the EU, compared to 73% in the US. This means that a quarter of the new medicines approved in the US are not approved in the EU and are thus not available to European patients. With a new European Parliament now elected and an EU legislative framework for medicines currently undergoing its biggest revision in decades, we are at a crossroads. In one direction a continuing - or indeed worsening - of this trend and in the other, a future-proof EU legislation which values, incentivizes, and rewards #innovation, benefiting #patients and ensuring the long-term #competitiveness of the European pharmaceutical industry. The revision of the EU legislative framework for medicines is an effort, which we, as the pharmaceutical industry, fully support. Initiated to increase patient access to medicines and foster an environment conducive to R&D in Europe, the legislative proposal - reducing Regulatory Data Protection from eight to six years for example - unfortunately fell short of addressing the needs for a thriving innovation-based pharmaceutical industry in and for Europe. The amendments that we have seen more recently by the (former) European Parliament are an improvement, but more is needed and there is much we can learn from others. Several governments around the world have made the life sciences a strategic priority, which results in venture capital funding for biotech, in fast clearances to start clinical development, quicker approvals and a market that is willing to pay for innovation. In Europe, by contrast, rather than considering innovation in the life sciences an investment we often viewit solely as a cost.  With a new 5-year term for the European Parliament and the Commission ahead of us, the new cohort of decision makers have the opportunity (and responsibility) to (re)set the direction and shape the future of research, development, and manufacturing for decades to come. And with the right legislation and ecosystem in place, we believe that the potential of medical innovation is limitless.  Together with Lars Fruergaard Jørgensen and David Loew, I remain committed to working with the new European Parliament, the EU Member States, and other stakeholders involved to change the trajectory of Europe for the better and strive for a more competitive, healthier, and stronger Europe.

“Our goal is to harness the power of gene therapy to improve patient lives globally,” Jude Samulski, co-founder and current board member of AskBio states while sharing his insights on the future of #genetherapy in a recently published article in Nature. This article shines a light on AskBio’s pioneering spirit and unwavering commitment to forging a new path where gene therapy can transform countless lives. At #AskBio, we are on the forefront of innovation, dedicated to advancing research and embracing cutting-edge science to revolutionize the field of gene therapy and make strides for a brighter future for all. Read the article (accessible with a subscription) and let us know what you think. https://lnkd.in/efQHZcmj

Today we announced the initiation of recruitment to REGENERATE-PD, a Phase 2 clinical study assessing the efficacy and safety of AB-1005, an investigational #genetherapy for the treatment of moderate-stage Parkinson’s disease. More than 10 million people worldwide suffer from Parkinson’s disease, with approximately 1 million living in the United States. #AskBio is dedicated to advancing research and embracing cutting-edge science to explore gene therapy solutions for this debilitating disease. For Medical Media – Read our press release here: https://lnkd.in/g478gFVH #ParkinsonsDisease

We are looking for a Senior Bioinformatician to join our team in Edinburgh, UK! Check out the job posting below and apply if interested. We will reach out if your qualifications match our needs. #hiring #edinburghUK #jobs #bioinformatician #AskBio Apply here: https://lnkd.in/eZDEGx6F Ross Fraser, Rosheen Caw

This #PrideMonth, #AskBio is excited to celebrate with our LGBTQ+ colleagues and the broader community. Led by our Employee Resource Group, next week we’re hosting a series of educational events and celebrations to honor diversity, foster inclusion, and celebrate the unique identities that make our workplace vibrant and strong. Diversity is strength. Be who you are with Pride. #Pride2024